Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans

Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with patho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS applied materials & interfaces 2019-09, Vol.11 (38), p.34676-34687
Hauptverfasser: Kesarwani, Vidhishri, Kelly, Hannah G, Shankar, Madhu, Robinson, Kye J, Kent, Stephen J, Traven, Ana, Corrie, Simon R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 34687
container_issue 38
container_start_page 34676
container_title ACS applied materials & interfaces
container_volume 11
creator Kesarwani, Vidhishri
Kelly, Hannah G
Shankar, Madhu
Robinson, Kye J
Kent, Stephen J
Traven, Ana
Corrie, Simon R
description Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality.
doi_str_mv 10.1021/acsami.9b10853
format Article
fullrecord <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_acsami_9b10853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>c949362287</sourcerecordid><originalsourceid>FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWwZYm8RkrxK2myhIhHRUU3sI7Gjl1cpU5lp0JlxT_wh3wJrlK6YzMzmnvuaHQRuqRkTAmjN6ACrOy4kJTkKT9CQ1oIkeQsZceHWYgBOgthSUjGGUlP0YBTkfOioEO0KN_Bg-q0t5_Q2dbh1uBnvcV3tv35-n4B1-Kpi3Jkohqw1N2H1g7P_SJqwTZWAd5ha_CdVY0OGFyNy1hsDRgaGQEXztGJgSboi30fobeH-9fyKZnNH6fl7SwBzkmXCKl4JgjNtDK6LgxnmYC8qFMWd5BmClIQBZGC5YwwxdVEZWaSSWoUlUzXfITG_V3l2xC8NtXa2xX4bUVJtUus6hOr9olFw1VvWG_kStcH_C-iCFz3QDRWy3bjXfz_v2u_BVp4uA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Kesarwani, Vidhishri ; Kelly, Hannah G ; Shankar, Madhu ; Robinson, Kye J ; Kent, Stephen J ; Traven, Ana ; Corrie, Simon R</creator><creatorcontrib>Kesarwani, Vidhishri ; Kelly, Hannah G ; Shankar, Madhu ; Robinson, Kye J ; Kent, Stephen J ; Traven, Ana ; Corrie, Simon R</creatorcontrib><description>Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality.</description><identifier>ISSN: 1944-8244</identifier><identifier>EISSN: 1944-8252</identifier><identifier>DOI: 10.1021/acsami.9b10853</identifier><identifier>PMID: 31483991</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Antifungal Agents - chemistry ; Antifungal Agents - pharmacology ; Candida albicans - growth &amp; development ; Candidiasis - drug therapy ; Candidiasis - metabolism ; Candidiasis - pathology ; Coated Materials, Biocompatible - chemistry ; Coated Materials, Biocompatible - pharmacology ; Humans ; Nanoparticles - chemistry ; Nanoparticles - therapeutic use ; Neutrophils - metabolism ; Organosilicon Compounds - chemistry ; Organosilicon Compounds - pharmacology ; Polyethylene Glycols - chemistry ; Polyethylene Glycols - pharmacology</subject><ispartof>ACS applied materials &amp; interfaces, 2019-09, Vol.11 (38), p.34676-34687</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</citedby><cites>FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</cites><orcidid>0000-0002-8539-4891 ; 0000-0001-8029-1896</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsami.9b10853$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsami.9b10853$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31483991$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kesarwani, Vidhishri</creatorcontrib><creatorcontrib>Kelly, Hannah G</creatorcontrib><creatorcontrib>Shankar, Madhu</creatorcontrib><creatorcontrib>Robinson, Kye J</creatorcontrib><creatorcontrib>Kent, Stephen J</creatorcontrib><creatorcontrib>Traven, Ana</creatorcontrib><creatorcontrib>Corrie, Simon R</creatorcontrib><title>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</title><title>ACS applied materials &amp; interfaces</title><addtitle>ACS Appl. Mater. Interfaces</addtitle><description>Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality.</description><subject>Antifungal Agents - chemistry</subject><subject>Antifungal Agents - pharmacology</subject><subject>Candida albicans - growth &amp; development</subject><subject>Candidiasis - drug therapy</subject><subject>Candidiasis - metabolism</subject><subject>Candidiasis - pathology</subject><subject>Coated Materials, Biocompatible - chemistry</subject><subject>Coated Materials, Biocompatible - pharmacology</subject><subject>Humans</subject><subject>Nanoparticles - chemistry</subject><subject>Nanoparticles - therapeutic use</subject><subject>Neutrophils - metabolism</subject><subject>Organosilicon Compounds - chemistry</subject><subject>Organosilicon Compounds - pharmacology</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Polyethylene Glycols - pharmacology</subject><issn>1944-8244</issn><issn>1944-8252</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWwZYm8RkrxK2myhIhHRUU3sI7Gjl1cpU5lp0JlxT_wh3wJrlK6YzMzmnvuaHQRuqRkTAmjN6ACrOy4kJTkKT9CQ1oIkeQsZceHWYgBOgthSUjGGUlP0YBTkfOioEO0KN_Bg-q0t5_Q2dbh1uBnvcV3tv35-n4B1-Kpi3Jkohqw1N2H1g7P_SJqwTZWAd5ha_CdVY0OGFyNy1hsDRgaGQEXztGJgSboi30fobeH-9fyKZnNH6fl7SwBzkmXCKl4JgjNtDK6LgxnmYC8qFMWd5BmClIQBZGC5YwwxdVEZWaSSWoUlUzXfITG_V3l2xC8NtXa2xX4bUVJtUus6hOr9olFw1VvWG_kStcH_C-iCFz3QDRWy3bjXfz_v2u_BVp4uA</recordid><startdate>20190925</startdate><enddate>20190925</enddate><creator>Kesarwani, Vidhishri</creator><creator>Kelly, Hannah G</creator><creator>Shankar, Madhu</creator><creator>Robinson, Kye J</creator><creator>Kent, Stephen J</creator><creator>Traven, Ana</creator><creator>Corrie, Simon R</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-8539-4891</orcidid><orcidid>https://orcid.org/0000-0001-8029-1896</orcidid></search><sort><creationdate>20190925</creationdate><title>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</title><author>Kesarwani, Vidhishri ; Kelly, Hannah G ; Shankar, Madhu ; Robinson, Kye J ; Kent, Stephen J ; Traven, Ana ; Corrie, Simon R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antifungal Agents - chemistry</topic><topic>Antifungal Agents - pharmacology</topic><topic>Candida albicans - growth &amp; development</topic><topic>Candidiasis - drug therapy</topic><topic>Candidiasis - metabolism</topic><topic>Candidiasis - pathology</topic><topic>Coated Materials, Biocompatible - chemistry</topic><topic>Coated Materials, Biocompatible - pharmacology</topic><topic>Humans</topic><topic>Nanoparticles - chemistry</topic><topic>Nanoparticles - therapeutic use</topic><topic>Neutrophils - metabolism</topic><topic>Organosilicon Compounds - chemistry</topic><topic>Organosilicon Compounds - pharmacology</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Polyethylene Glycols - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kesarwani, Vidhishri</creatorcontrib><creatorcontrib>Kelly, Hannah G</creatorcontrib><creatorcontrib>Shankar, Madhu</creatorcontrib><creatorcontrib>Robinson, Kye J</creatorcontrib><creatorcontrib>Kent, Stephen J</creatorcontrib><creatorcontrib>Traven, Ana</creatorcontrib><creatorcontrib>Corrie, Simon R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>ACS applied materials &amp; interfaces</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kesarwani, Vidhishri</au><au>Kelly, Hannah G</au><au>Shankar, Madhu</au><au>Robinson, Kye J</au><au>Kent, Stephen J</au><au>Traven, Ana</au><au>Corrie, Simon R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</atitle><jtitle>ACS applied materials &amp; interfaces</jtitle><addtitle>ACS Appl. Mater. Interfaces</addtitle><date>2019-09-25</date><risdate>2019</risdate><volume>11</volume><issue>38</issue><spage>34676</spage><epage>34687</epage><pages>34676-34687</pages><issn>1944-8244</issn><eissn>1944-8252</eissn><abstract>Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>31483991</pmid><doi>10.1021/acsami.9b10853</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-8539-4891</orcidid><orcidid>https://orcid.org/0000-0001-8029-1896</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1944-8244
ispartof ACS applied materials & interfaces, 2019-09, Vol.11 (38), p.34676-34687
issn 1944-8244
1944-8252
language eng
recordid cdi_crossref_primary_10_1021_acsami_9b10853
source MEDLINE; American Chemical Society Journals
subjects Antifungal Agents - chemistry
Antifungal Agents - pharmacology
Candida albicans - growth & development
Candidiasis - drug therapy
Candidiasis - metabolism
Candidiasis - pathology
Coated Materials, Biocompatible - chemistry
Coated Materials, Biocompatible - pharmacology
Humans
Nanoparticles - chemistry
Nanoparticles - therapeutic use
Neutrophils - metabolism
Organosilicon Compounds - chemistry
Organosilicon Compounds - pharmacology
Polyethylene Glycols - chemistry
Polyethylene Glycols - pharmacology
title Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A30%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20Key%20Bio%E2%80%93Nano%20Interactions%20between%20Organosilica%20Nanoparticles%20and%20Candida%20albicans&rft.jtitle=ACS%20applied%20materials%20&%20interfaces&rft.au=Kesarwani,%20Vidhishri&rft.date=2019-09-25&rft.volume=11&rft.issue=38&rft.spage=34676&rft.epage=34687&rft.pages=34676-34687&rft.issn=1944-8244&rft.eissn=1944-8252&rft_id=info:doi/10.1021/acsami.9b10853&rft_dat=%3Cacs_cross%3Ec949362287%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31483991&rfr_iscdi=true